Serum value of fasting C-peptide (FC-P), fasting insulin (FIns), and glycated hemoglobin (HbA1c) after dynamic blood glucose monitoring-guided personalised nutrition and insulin pump therapy for type II diabetes mellitus

动态血糖监测指导下的个体化营养和胰岛素泵治疗对II型糖尿病患者空腹C肽(FC-P)、空腹胰岛素(FIns)和糖化血红蛋白(HbA1c)血清值的影响

阅读:1

Abstract

BACKGROUND: Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterised by impaired glucose metabolism, which necessitates comprehensive management of blood glucose (BG), blood pressure, and lipid profiles. This study aimed to evaluate the clinical effects of individualised nutrition and insulin pump therapy, guided by continuous glucose monitoring (CGM) and the Quality Circle Control (QCC) nursing model, on various biomarkers in T2DM patients, including fasting C-peptide (FC-P), fasting plasma glucose (FPG), 2-hour postprandial glucose (2hPG), fasting insulin (FIns), and glycated haemoglobin (HbA1c). METHODS: Eighty T2DM patients treated at our hospital were enrolled in the study between January 2023 and January 2024. Patients were assigned to either the experimental group (EG), which received individualised nutrition and insulin pump therapy supported by CGM and the QCC nursing model, or the regular group (RG), which received standard care. Differences in BG control, insulin usage, CGM system performance (including downtime and anomaly rates), and patient satisfaction were compared between the two groups. RESULTS: The EG demonstrated significant improvements in FC-P, FPG, 2hPG, FIns, and HbA1c levels compared to the RG (P<0.05). Specifically, the EG showed more rapid achievement of BG targets, reduced glucose variability, lower insulin usage, and decreased CGM system anomalies. CONCLUSIONS: The QCC nursing model, when integrated with individualised nutrition and insulin pump therapy guided by CGM, significantly enhances blood glucose control, optimises insulin therapy, and improves patient outcomes, including dietary habits, quality of life, and reduction in hypoglycemic events. This model shows promise as an effective strategy for managing T2DM and warrants further adoption in clinical practice.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。